In a nation of complicated legal machinations, the mifepristone situation is especially complicated. U.S. District Judge Matthew Kacsmaryk last week suspended a number of laws regulating the popular and widely-used abortion drug mifepristone. Kacsmaryk’s ruling affected both the Food and Drug Administration's original 2000 approval of mifepristone as well as subsequent updates to laws regulating the drug from 2016 and 2019. Multiple appeals to Kacsmaryk’s ruling followed, and late this week the Supreme Court issued an administrative stay on the lower court’s ruling in the aftermath of a formal request from the Justice Department to block the new restrictions to the drug. Limiting access to mifepristone would have far-reaching implications of the ability of the FDA to approve other drugs, and to further complicate the situation, a ruling out of Washington was issued that could potentially limit Kacsmaryk’s decision. As the story develops in real time, Jessica updates you on the current state of the law surrounding mifepristone, as well as how we got here and where the law is going.